EI
STRO icon

EAM Investors’s Sutro Biopharma STRO Stock Holding History

EAM Investors’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5,264
Closed -$1.2M – 429
2021
Q1 		$1.2M Sell
5,264
-3,289
-38% -$780K 0.18% 271
2020
Q4 		$1.86M Buy
+8,553
New +$1.42M 0.3% 145

Other funds holding STRO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

EAM Investors's STRO Position: Q2 2021 in Review

EAM Investors sold out of Sutro Biopharma (STRO) in Q2 2021, closing a stake of 5,264 shares — an estimated $1.2M sold.

EAM Investors first reported a position in STRO in Q4 2020 and held it in 2 quarters. The position peaked at $1.86M in Q4 2020. 124 funds tracked by Wall St. Rank hold STRO as of Q2 2021.

  • EAM Investors reported no remaining Sutro Biopharma position as of Q2 2021 after selling out during the quarter.
  • EAM Investors sold 5,264 Sutro Biopharma shares in Q2 2021, an estimated $1.2M.
  • EAM Investors first reported a position in Sutro Biopharma in Q4 2020 and held it in 2 quarters.
  • EAM Investors's Sutro Biopharma position peaked at $1.86M in Q4 2020.
  • 124 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2021.

Based on EAM Investors's 13F filing for Q2 2021, filed 13 Aug 2021.